Cardiometabolic Risk FactorsFILIPNCT06640036
FILIP: Fat Intake, Inflammation and LIPids
A study testing Rapeseed oil, Butter and Coconut oil in people with Cardiometabolic Risk Factors and Inflammation, run by Göteborg University at 1 site in Sweden.
Trial summary
Low-grade inflammation is involved in the pathogenesis of type 2 diabetes and cardiovascular disease. Increasing evidence suggests that dietary intake may be involved in the inflammatory process. How nutritional composition of the diet affects the inflammatory response is however not well understood. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiometabolic Risk Factors, Inflammation, Microbiota
- What is being tested?
- Rapeseed oil, Butter and Coconut oil
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteSweden
- Study dates
- 8 Apr 2025to 17 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-60
- Willing to eat the study diet
Who cannot join
- malabsorption-related condition
- contraindications to consume a high fat diet
- intolerance to any foods used in the study (e.g. cow's milk, egg, gluten)
- established cardiovascular disease, diabetes or cancer
- current use of medication known to affect lipid metabolism (e.g. statins) or inflammation (e.g. NSAID, glucocorticoids).
- hemoglobin \<100 g/L
- ongoing pregnancy or lactation
Trial locations and contacts
1 site in 1 country.
About this study
Low-grade inflammation is involved in the pathogenesis of type 2 diabetes and cardiovascular disease. Increasing evidence suggests that dietary intake may be involved in the inflammatory process. How nutritional composition of the diet affects the inflammatory response is however not well understood.
The aim of this project is to study if intake of three different fat sources induce different effects on inflammation markers, blood lipids, blood glucose and the microbiota.
- Conditions
- Cardiometabolic Risk Factors, Inflammation, Microbiota
- Being tested
- Rapeseed oil, Butter, Coconut oil
- Keywords
- Blood lipid profile, Low grade inflammation
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rapeseed oilOther
During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
ButterOther
During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
Coconut oilOther
During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
| Study group | Role | What they receive |
|---|---|---|
| Sequence 1: Rapeseed oil, butter, coconut oil | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
| Sequence 2: Rapeseed oil, coconut oil, butter | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
| Sequence 3: Butter, coconut oil , rapeseed oil | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
| Sequence 4: Butter, rapeseed oil, coconut oil | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
| Sequence 5: Coconut oil, rapeseed oil, butter | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
| Sequence 6: Coconut oil, butter, rapeseed oil | Experimental | Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals Receives: Other: Rapeseed oil; Other: Butter; Other: Coconut oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total cholesterol
Measured: Baseline and 1 week
hs-CRP
High sensitivity C-reactive Protein
Measured: Baseline and 1 week
Secondary outcomes (4)
Inflammation markers
Eg. GlycA, IL6, TNF-a
Measured: Baseline and 1 week
Blood lipid propfile
Blood lipids and their subfractions, lipoproteins, apolipoproteins
Measured: Baseline and 1 week
Glucose
Glucose, measured by continuous blood glucose monitoring
Measured: Continuous during 1 week
Microbiota
Change in gut microbial composition and diversity (alpha- and beta).
Measured: Baseline and 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start8 Apr 2025
- Primary completion17 Dec 2025
- Study completion17 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiometabolic Risk FactorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- Göteborg University
- Sponsor type
- University, hospital or other
- Collaborators
- Chalmers University of Technology
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06640036
- Sponsor's protocol ID
- 2024-03117-01
- Acronym
- FILIP
- Status last verified
- Apr 2025
- First submitted
- 10 Oct 2024
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It would depend on ethical permission to share the IPD.
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- FILIP: Fat Intake, Inflammation and LIPids
- ClinicalTrials.gov ID
- NCT06640036
- Acronym / sponsor ID
- FILIP / 2024-03117-01
- Conditions
- Cardiometabolic Risk Factors, Inflammation, Microbiota
- Keywords
- Blood lipid profile, Low grade inflammation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- Göteborg UniversityUniversity, hospital or other
- Collaborators
- Chalmers University of Technology
- Study start
- 8 Apr 2025 (actual)
- Primary completion
- 17 Dec 2025 (actual)
- Study completion
- 17 Dec 2025 (actual)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low-grade inflammation is involved in the pathogenesis of type 2 diabetes and cardiovascular disease. Increasing evidence suggests that dietary intake may be involved in the inflammatory process. How nutritional composition of the diet affects the inflammatory response is however not well understood.
The aim of this project is to study if intake of three different fat sources induce different effects on inflammation markers, blood lipids, blood glucose and the microbiota.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Sequence 1: Rapeseed oil, butter, coconut oil | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
| Sequence 2: Rapeseed oil, coconut oil, butter | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
| Sequence 3: Butter, coconut oil , rapeseed oil | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
| Sequence 4: Butter, rapeseed oil, coconut oil | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
| Sequence 5: Coconut oil, rapeseed oil, butter | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
| Sequence 6: Coconut oil, butter, rapeseed oil | Experimental | Other: Rapeseed oil, Other: Butter, Other: Coconut oilDiets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Age 18-60
- Willing to eat the study diet
Key exclusion criteria (7 listed)
- malabsorption-related condition
- contraindications to consume a high fat diet
- intolerance to any foods used in the study (e.g. cow's milk, egg, gluten)
- established cardiovascular disease, diabetes or cancer
- current use of medication known to affect lipid metabolism (e.g. statins) or inflammation (e.g. NSAID, glucocorticoids).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rapeseed oilDuring 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals. | Other | Sequence 1: Rapeseed oil, butter, coconut oil, Sequence 2: Rapeseed oil, coconut oil, butter, Sequence 3: Butter, coconut oil , rapeseed oil, Sequence 4: Butter, rapeseed oil, coconut oil, Sequence 5: Coconut oil, rapeseed oil, butter, Sequence 6: Coconut oil, butter, rapeseed oil |
| ButterDuring 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals. | Other | Sequence 1: Rapeseed oil, butter, coconut oil, Sequence 2: Rapeseed oil, coconut oil, butter, Sequence 3: Butter, coconut oil , rapeseed oil, Sequence 4: Butter, rapeseed oil, coconut oil, Sequence 5: Coconut oil, rapeseed oil, butter, Sequence 6: Coconut oil, butter, rapeseed oil |
| Coconut oilDuring 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals. | Other | Sequence 1: Rapeseed oil, butter, coconut oil, Sequence 2: Rapeseed oil, coconut oil, butter, Sequence 3: Butter, coconut oil , rapeseed oil, Sequence 4: Butter, rapeseed oil, coconut oil, Sequence 5: Coconut oil, rapeseed oil, butter, Sequence 6: Coconut oil, butter, rapeseed oil |
Primary outcome
Total cholesterol
Time frame: Baseline and 1 week
hs-CRP
Time frame: Baseline and 1 week
High sensitivity C-reactive Protein
4 secondary outcomes
Inflammation markers
Time frame: Baseline and 1 week
Blood lipid propfile
Time frame: Baseline and 1 week
Glucose
Time frame: Continuous during 1 week
Microbiota
Time frame: Baseline and 1 week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: Undecided. It would depend on ethical permission to share the IPD.
Related trials for Cardiometabolic Risk Factors
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health
Active, not recruiting
Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function
Inflammation Biomarkers, Oxidative Stress
Recruiting
Sustainable Diets and Cardiometabolic Health
Cardiometabolic Diseases
Recruiting
Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke
Stroke, Ischemic
Active, not recruitingPhase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rapeseed oil, Butter and Coconut oil in people with Cardiometabolic Risk Factors and Inflammation, run by Göteborg University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total cholesterol (time frame: Baseline and 1 week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.